2026-01-27 - Analysis Report
**Comprehensive Report for Novo Nordisk (NVO)**

### 1. Company Overview
Novo Nordisk is a Danish multinational pharmaceutical company specializing in diabetes, obesity, and other serious chronic diseases.

### 2. Return Rates and Divergence
* Cumulative return of review stock (NVO): 100.63%
* Cumulative return of comparison stock (S&P 500, VOO): 127.58%
* Divergence: -31.20 (Relative divergence: 13.10%)

### Analysis
Novo Nordisk's return rate lags behind the S&P 500's, indicating a moderate divergence.

### 3. Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 4.0% | 18.2% | -5.0% | 0.8 | 102.4B |
| 2017-2019  | 54.0% | 14.1% | 29.0% | 0.6 | 128.6B |
| 2018-2020  | 23.0% | 23.6% | -1.0% | 0.6 | 155.2B |
| 2019-2021  | 118.0% | 23.6% | 54.0% | 0.6 | 248.8B |
| 2020-2022  | 116.0% | 23.6% | 111.0% | 0.6 | 300.7B |
| 2021-2023  | 208.0% | 19.9% | 190.0% | 0.5 | 459.7B |
| 2022-2024  | 78.0% | 41.1% | 48.0% | 0.5 | 382.2B |
| 2023-2025  | -98.0% | 67.0% | -174.0% | 0.7 | 226.1B |

### Analysis
Novo Nordisk's alpha and beta values indicate a moderate level of risk. The company's CAGR is generally high, with the exception of 2023-2025.

### 4. Stock Price Fluctuations
* Close: $63.98
* Last-market: $63.98 - $62.26 (+2.76)
* 5-day Moving Average: $61.69
* 20-day Moving Average: $57.44
* 60-day Moving Average: $51.46

### Analysis
The current price of Novo Nordisk is slightly above the 20-day and 60-day moving averages, indicating a short-term upward trend.

### 5. RSI, PPO Index Indicators
* Market Risk Indicator (MRI): 0.70
* RSI: 71.77
* PPO: 0.60
* Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.70)
Recent (20 days) relative divergence change: 4.50 (+): improving
7-day Rank change: 0 (0): flat
7-day Dynamic Expected Return change: 769.20 (+): improving
Expected Return (%): 985.20%
Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

### Analysis
The RSI and PPO indicators suggest a moderate level of risk. The market risk indicator is at a medium level, indicating a moderate level of investment risk.

### 6. Recent News & Significant Events
* [2026-01-25] Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog (NYSE:NVO) - Seeking Alpha
* [2026-01-25] Is Novo Nordisk (NYSE:NVO) Still Attractive After Recent 27.8% One-Year Share Price Decline? - Yahoo Finance
* [2026-01-26] Prediction: This Healthcare Stock Could Soar by 40% in 2026 - The Motley Fool
* [2026-01-23] Novo Nordisk Stock (NVO) Gains on Obesity Pill Demand as Goldman Flags Earnings Upside - TipRanks
* [2026-01-26] Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview) (NYSE:NVO) - Seeking Alpha
* [2026-01-23] Novo Nordisk: This Run Is Just Getting Started (NYSE:NVO) - Seeking Alpha

### Analysis
The recent news suggests that Novo Nordisk is gaining momentum, with several analysts predicting a significant increase in its stock price in the coming year.

### 7. Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 59.18 / 74.93 / 42.59

### Analysis
The analyst consensus suggests that Novo Nordisk is a buy, with a moderate level of optimism among analysts.

### 8. Comprehensive Analysis
Novo Nordisk's return rate lags behind the S&P 500's, indicating a moderate divergence. The company's alpha and beta values indicate a moderate level of risk. The RSI and PPO indicators suggest a moderate level of risk. The market risk indicator is at a medium level, indicating a moderate level of investment risk. The recent news suggests that Novo Nordisk is gaining momentum, with several analysts predicting a significant increase in its stock price in the coming year. The analyst consensus suggests that Novo Nordisk is a buy, with a moderate level of optimism among analysts.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.